期刊文献+

静脉用蔗糖铁治疗血液透析患者肾性贫血的疗效观察及护理 被引量:2

Observation of Effect of Intravenous Iron Sucrose in Hemodialysis in Treatment of Patients with Renal Anemia and Its Nursing
原文传递
导出
摘要 目的探讨静脉补铁对肾性贫血的疗效及护理。方法 46例维持血液透析的贫血患者分为静脉和口服两组,治疗8周后观察其Hb、RBC等各项指标的变化。结果静脉组治疗前后的Hb为(70.05±16.19)g/L及(86.19±13.04)g/L,RBC为(2.51±0.56)×1012/L及(3.08±0.65)×1012/L,Hct为0.218±0.051及0.274±0.046,SF为(215.43±98.31)μg/L及(510.99±136.96)μg/L,TSAT为(21.03±5.83)%及(33.51±7.47)%,差异具有统计学意义(P均<0.01);且Hb、Hct、SF、TSAT增高幅度明显高于口服组(P<0.05)。口服组治疗前后各指标均无统计学差异。结论静脉补铁治疗血液透析患者肾性贫血疗效优于口服铁剂。 Objective To explore the effect and nursing of intravenous iron therapy in renal anemia.Methods 46 anaemic patients with maintenance hemodialysis were divided into intravenous group and oral group.The indicators of Hb、RBC、etc were observed after treatment for 8 weeks.Result The Hb was(70.05±16.19) g/L and(86.19±13.04)g/L,and the RBC was(2.51±0.56)×1012/L and(3.08±0.65)×1012/L,and the Hct was 0.218±0.051 and 0.274±0.046,the SF was(215.43±98.31) μg/L and(510.99±136.96)μg/L,the TSAT was(21.03±5.83)% and(33.51±7.47)%.The difference had a statistical significance(P0.01).The increases extent of Hb、Hct、SF、TSAT was obvious higher in ntravenous group than in oral group.There was no statistical difference in oral group before and after treatment.Conclusion The effect of intravenous iron therapy is better than oral iron therapy in treatment of renal anemia by hemodialysis.
出处 《中国误诊学杂志》 CAS 2010年第23期5559-5560,共2页 Chinese Journal of Misdiagnostics
关键词 肾透析/副作用 贫血/病因学/药物疗法 铁化合物/治疗应用 人类 Kidney dialysis/side effect Anemia/nosetiology/pharmacotherapy Iron compound/therapeutic use Human
  • 相关文献

参考文献6

二级参考文献15

  • 1唐琦,汪关煜,钱莹,朱萍,沈平雁.肾性贫血时静脉与口服铁剂的疗效比较[J].中国血液净化,2004,3(8):431-434. 被引量:38
  • 2Locatelli F,Pisoni RL,Combe C,et al.Anaemia in haemodialysis patients of five European countries:association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).Nephrol Dial transplant,2004,19:121 - 132. 被引量:1
  • 3王海燕主译.慢性肾脏病及透析的临床实践指南.第4版.北京:人民卫生出版社,2003.293-306. 被引量:1
  • 4Seiler S.Anemia of chronic renal failure:new treatment alternative.CANNT J,2000,10:35 - 39. 被引量:1
  • 5EschbachJW,EgrieJC,DowningMR.Correctionoftheanemiaofend-stagerenaldiseasewithrecombinanthumanerythropoietin[].The New England Journal of Medicine.1987 被引量:1
  • 6MacdougallIC.Monitoringofironstatusandironsupplementationinpatientstreatedwitherythropoietin[].CurrOpinionNephrolHy-pertens.1994 被引量:1
  • 7LevinNW,LazarusJM,NissensonAR.NationalCooperativerHuErythropoietinStudyinpatientswithchronicrenalfailure:aninterimreport[].AmJKidneyDis.1993 被引量:1
  • 8.NKF-DOQIclinicalpracticeguidelinesforthetreatmentofanemiaofchronicrenalfailure[].AmJKidneyDis.1997 被引量:1
  • 9CharytanC,LevinN,SaloumMA.Efficacyandsafetyofironsucroseforirondeficiencyinpatientswithdialysis-associatedanemia:NorthAmericanClinicalTrial[].AmJKidneyDis.2001 被引量:1
  • 10MichaelB,CoyneDW,StevenC.Sodiumferricgluconatecom-plexinhemodialysispatients:adversereactionscomparedtoplaceboandirondextran[].Kidney International.2002 被引量:1

共引文献314

同被引文献17

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部